Peng Rou-Jun | Medical Oncology | Sun Yat-sen University Cancer Center-Sun Yat-sen University Cancer Center

Name: Peng Rou-Jun

Title: Associate Professor

Email: pengrj@sysucc.org.cn

Phone:

Profile

Dr. Rou-Jun Peng is associated professor of Department of Medical Oncology, Sun Yat-sen University Cancer Center. Dr. Peng obtained her Bachelor in Medicine (equivalent to MD in the US) and PhD at Sun Yat-sen University, P. R. China in 2000 and 2011, respectively. She had the collaborateive PhD student training at Karolinska Institutet, Sweden from Sep 2008 to Sep 2010, which provided her with great opportunities to explore the fields of lymphoma pathologenesis. She joined the Department of Medical Oncology at Sun Yat-sen University Cancer Center (SYSUCC) as a associated Professor in Dec 2013. Dr. Peng has published more than 20 research papers. Now Dr. Peng’s clinical specialty is the treatment of breast cancer, and the research interest is in the field of breast caner biology.

Interests

Dr. Rou-Jun Peng is interested in the mechanism of resistance to Traustuzumab in ErbB2 overexpression breast cancer, the molecular biology of triple-negative breast cancer, the mechanism of circulating tumor cell to metastasis of breast cancer. She specialized in the treatment of breast cancer.

Education

1995-2000:Medical College, Sun Yat-Sen University. Awarded a Bachelor degree of Medicine.

2003-2007: Sun Yat-Sen University.Awarded a Master degree of Clinical Oncology.

2007-2011: Sun Yat-SenUniversity. Awarded a PhD degree of Oncology.

2008-2010: Karolinska Institutet,Sweden. Collaborative training for PhD student.

Publications

1. de Miranda NF, Peng R, Georgiou K, Wu C,Falk Sörqvist E, Berglund M, Chen L, Gao Z, Lagerstedt K, Lisboa S, Roos F, vanWezel T, Teixeira MR, Rosenquist R, Sundström C, Enblad G, Nilsson M, Zeng Y,Kipling D, Pan-Hammarström Q. 2013. DNA repair genes are selectively mutated indiffuse large B cell lymphomas. J Exp Med 210: 1729-42. [co-first author].

2. DuL, Peng RJ, Bjorkman A, Filipe de Miranda N, Rosner C, Kotnis A, Berglund M,Liu C, Rosenquist R, Enblad G, Sundstrom C, Hojjat-Farsangi M, Rabbani H,Teixeira MR, Revy P, Durandy A, Zeng Y, Gennery AR, de Villartay JP,Pan-Hammarstrom Q. 2012. Cernunnos influences human immunoglobulin class switchrecombination and may be associated with B cell lymphomagenesis. J Exp Med 209:291-305. [co-first author].

3. Peng RJ, Huang ZF, Zhang YL, Yuan ZY, XiaY, Jiang WQ, Zeng YX, Li J. 2011. Circulating and tumor-infiltrating Foxp3(+)regulatory T cell subset in Chinese patients with extranodal NK/T celllymphoma. Int J Biol Sci 7: 1027-36.

4. Peng RJ, Wang S, Shi Y, LiuD, Teng X, Qin T, Zeng Y, Yuan Z. 2011. Patients 35 years old or younger withoperable breast cancer are more at risk for relapse and survival: aretrospective matched case-control study. Breast 20: 568-73.

5. Xia Q, Cai Y, Peng RJ, Wu G, Shi Y, JiangW. 2014. The CDK1 inhibitor RO3306 improves the response of BRCA-proﬁcientbreast cancer cells to PARP inhibition. Int J Onco 44:735-44.

6. Tan DE, Foo JN, Bei JX, Chang J, Peng RJ, Zheng X, Wei L, HuangY, Lim WY, Li J, Cui Q, Chew SH, Ebstein RP, Kuperan P, Lim ST, Tao M, Tan SH,Wong A, Wong GC, Tan SY, Ng SB, Zeng YX, Khor CC, Lin D, Seow AL, Jia WH, LiuJ. 2013. Genome-wide association study of B cell non-Hodgkin lymphomaidentifies 3q27 as a susceptibility locus in the Chinese population. Nat Genet45:804-7.

7. Qin T, Yuan Z, Peng RJ, Bai B, Shi Y, TengX, Liu D, Wang S. 2013. HER2-positive breast cancer patients receivingtrastuzumab treatment obtain prognosis comparable with that of HER2-negativebreast cancer patients. Onco Targets Ther 6:341-7.

8. Xue C, Wang X, Peng RJ, Shi Y, Qin T,Liu D, Teng X, Wang S, Zhang L, Yuan Z. 2012. Distribution, clinicopathologicfeatures and survival of breast cancer subtypes in Southern China. Cancer Sci103: 1679-83.

9. Shi YX, Xia Q, Peng RJ, Yuan ZY, Wang SS, An X, Cao Y, TanYT, Jin Y, Cai XY, Sun YL, Teng XY, Liu DG, Jiang WQ. 2012. Comparison ofclinicopathological characteristics and prognoses between bilateral andunilateral breast cancer. J Cancer Res Clin Oncol 138: 705-14.

10.Shi YX, Tan YT, Yuan ZY, Wang SS, Peng RJ, AnX, Cao Y, Jin Y, Cai XY, Sun YL, Teng XY, Liu DG. 2012. Comparison of overallsurvival between the early use and delayed use of Trastuzumab therapy groups: aretrospective analysis of 128 patients with HER-2-positive advanced breastcancer. Med Oncol 29: 39-47.

11. Wang X, Wang SS, Peng RJ, Qin T, Shi YX, Teng XY,Liu DG, Chen WQ, Yuan ZY. 2012. Interaction of coping styles and psychologicalstress on anxious and depressive symptoms in chinese breast cancer patients.Asian Pac J Cancer Prev 13: 1645-9.

12. Liu DG, Wang SS, Peng RJ, Qin T, Shi YX, TengXY, Wang X, Chen WQ, Yuan ZY. 2012. Interaction of social support andpsychological stress on anxiety and depressive symptoms in breast cancerpatients. Asian Pac J Cancer Prev 12: 2523-9.

13. Liu D, He J, Yuan Z, Wang S, Peng RJ, Shi Y,Teng X, Qin T. 2012. EGFR expression correlates with decreased disease-freesurvival in triple-negative breast cancer: a retrospective analysis based on atissue microarray. Med Oncol 29: 401-5.

14. He J, Peng RJ, Yuan Z, Wang S, Peng J, Lin G,Jiang X, Qin T. 2012. Prognostic value of androgen receptor expression inoperable triple-negative breast cancer: a retrospective analysis based on atissue microarray. Med Oncol 29: 406-10.

15. Liu P, Fang X, Feng Z, Guo YM, Peng RJ, LiuT, Huang Z, Feng Y, Sun X, Xiong Z, Guo X, Pang SS, Wang B, Lv X, Feng FT, LiDJ, Chen LZ, Feng QS, Huang WL, Zeng MS, Bei JX, Zhang Y, Zeng YX. 2011. Directsequencing and characterization of a clinical isolate of Epstein-Barr virusfrom nasopharyngeal carcinoma tissue by using next-generation sequencingtechnology. J Virol 85: 11291-9.

16. Gu AD, Mo HY, Xie YB, Peng RJ, Bei JX, Peng J,Li MY, Chen LZ, Feng QS, Jia WH, Zeng YX. 2008. Evaluation of a multianalyteprofiling assay and an enzyme-linked immunosorbent assay for serologicalexamination of Epstein-Barr virus-specific antibody responses in diagnosis ofnasopharyngeal carcinoma. Clin Vaccine Immunol 15: 1684-8.

17. Peng RJ, Sun XF, Xiang XJ, Zhen ZJ, Ling JY,Tong GL, Xia Y, Xu GC, Jiang WQ. 2009. [Efficacy and survival of 92 cases ofEwing's sarcoma family of tumor initially treated with multidisciplinarytherapy]. Ai Zheng 28: 1304-9.

18. Shi YX, Peng RJ, Lin SX, Wu QL, Lin TY, SunXF, Huang HQ, Xia ZJ, Li YH, Xu RH, Liu DG, Guan ZZ, Jiang WQ. 2007. [A survivalof 103 cases of T-cell non-Hodgkin lymphoma]. Zhonghua Nei Ke Za Zhi 46:1000-2.

19. Shi YX, Han WJ, Peng RJ., etal. Screening of RNA Intervening Targets of foxp3 Gene with FLAG Fusion Peptideand Lentivirus Vector. Journal of Sun Yat-Sen University (Medical Sciences).2007,28(6):641-644.

20. Peng RJ, Q.M. Dong, Y.X. Shi, Y. Cao,Z.M. Zhou, Z.Y. Yuan, S. Li, H. Liao, W.Q. Jiang. 2006. Correlative analysisbetween serum dihydropyrimidine dehydrogenase, activity, concentration of5-fluorouracil and adverse events in the treatment of advanced gastric cancerpatients. Ai Zheng 25:1039-1043.

21. Liu, D.G., R.J. Peng, F.Y. Feng, X.H.Hu, G.D. Tang, J.P. Xiong, H.Y. Zhao, Y. Guo, and Z.Z. Guan. 2006. Randomizedcontrolled trial of two kinds of home-produced docetaxel in China for advancedbreast cancer. Ai Zheng 25:1557-1560.

22. Li, Z.G., Y.X. Shi, R.J. Peng, M.Q. Zhu, andY.Y. Wan. 2006. Blocking enhancive effect of vascular endothelial growth factoron proliferation of rhabdomyosarcoma cell line RH4 by avastin. Ai Zheng25:718-722.

23. Cao Y, Li HL, R.J. Peng, et al. Design stageI clinical trial of target, non-cytotoxic agents. Journal of Sun Yat-SenUniversity (Medical Sciences). 2006,28(4s): 44-46.

Updated by International Office, Sun Yat-sen University Cancer Center

Our Experts